Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023 4:06 PM ESTQ4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. DAXXIFY® Q4 PrevU revenue of $11.0 million, with commercial launch to begin late March 2023. PDUFA date for DAXXIFY® for the treatment of cervical dystonia of August 19, 2023. Appointed Dr. Vlad Coric, M.D., Chairman and CEO of Biohaven, to the companys Board of Directors. Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS... More
